Exchange: NASDAQ Capital Market Sector: Healthcare Industry: Biotechnology
3.16% $0.0750
/ 7 sep 2022 @ 16:00
RATING 2022-11-09 |
---|
B+ |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Strong Buy | |
Return On Equity: | Strong Sell | |
Return On Asset: | Strong Sell | |
DE: | Strong Buy | |
P/E: | Sell | |
Price To Book: | Strong Buy |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
1/21 | 2/21 | 3/21 | 4/21 | 1/22 | 2/22 | |
Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
Gr.Profit | n/a | n/a | n/a | n/a | n/a | n/a |
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -0.118 | sector: PE 0 |
PE RATIO: COMPANY / INDUSTRY |
---|
0x |
Company: PE -0.118 | industry: PE 0 |
DISCOUNTED CASH FLOW VALUE |
---|
N/A |
N/A |
Expected Trading Range (DAY) |
---|
$ 0.0550 - 0.0950 ( +/- 26.67%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2022-02-01 | Katz Richard D | Buy | 255 000 | Restricted Stock Units |
2022-02-01 | Brenner Louis Md | Buy | 655 000 | Restricted Stock Units |
2021-11-15 | Brenner Louis Md | Buy | 125 582 | Common Stock |
2021-11-15 | Brenner Louis Md | Sell | 40 328 | Common Stock |
2021-11-15 | Brenner Louis Md | Sell | 125 582 | Restricted Stock Units |
INSIDER POWER |
---|
0.00 |
Last 96 transactions |
Buy: 22 244 841 | Sell: 65 238 655 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $0.0750 (3.16% ) |
Volume | 252.31 mill |
Avg. Vol. | 0 mill |
% of Avg. Vol | 0 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
Allena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. Its lead product candidate is ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and gout in the setting of advanced chronic kidney disease. The company was incorporated in 2011 and is headquartered in Newton, Massachusetts.